FULGENT GENETICS, INC. (FLGT) Current Ratio
- Current ratio · latest quarter: Value 6.34×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.34× | Current assets / current liabilities. $454.77M ÷ $71.76M ≈ 6.34× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 454.77M USD | Assets, Current |
| Current obligations | 71.76M USD | Liabilities, Current |
| Cash and equivalents | 26.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 230.73M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 64.94M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 793.00K USD | Inventory, Net |
| Payables | 15.55M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $454.77M | $71.76M | $26.30M | $230.73M | $64.94M | $793.00K | $15.55M | (m) | 6.34× |
| 2026-03-31 | $479.04M | $90.13M | $23.40M | $252.90M | $69.28M | $770.00K | $21.13M | (m) | 5.31× |
| 2025-12-31 | $550.49M | $84.97M | $50.19M | $285.88M | $84.76M | (m) | $18.65M | (m) | 6.48× |
| 2025-09-30 | $507.37M | $72.43M | $117.64M | (m) | $71.19M | (m) | $18.09M | (m) | 7.01× |
| 2025-06-30 | $428.73M | $71.33M | $87.88M | (m) | $77.19M | (m) | $18.89M | (m) | 6.01× |
| 2025-03-31 | $416.78M | $65.92M | $67.28M | (m) | $71.48M | (m) | $18.24M | (m) | 6.32× |
| 2024-12-31 | $353.57M | $72.90M | $55.14M | $202.96M | $69.02M | (m) | $18.36M | (m) | 4.85× |
| 2024-09-30 | $326.54M | $73.99M | $58.04M | (m) | $57.31M | (m) | $19.80M | (m) | 4.41× |
| 2024-06-30 | $399.10M | $75.75M | $65.11M | (m) | $56.57M | (m) | $19.87M | (m) | 5.27× |
| 2024-03-31 | $386.51M | $75.95M | $54.68M | (m) | $52.06M | (m) | $19.62M | (m) | 5.09× |
| 2023-12-31 | $507.85M | $73.02M | $97.47M | (m) | $51.13M | (m) | $15.36M | (m) | 6.96× |
| 2023-09-30 | $549.86M | $61.42M | $84.08M | (m) | $49.28M | (m) | $15.77M | (m) | 8.95× |
| 2023-06-30 | $528.29M | $64.82M | $58.35M | (m) | $34.81M | (m) | $20.61M | (m) | 8.15× |
| 2023-03-31 | $580.72M | $81.94M | $66.17M | (m) | $43.55M | (m) | $22.08M | (m) | 7.09× |
| 2022-12-31 | $627.87M | $88.11M | $79.51M | (m) | $52.75M | (m) | $23.09M | (m) | 7.13× |
| 2022-09-30 | $696.61M | $102.52M | $168.77M | (m) | $104.16M | (m) | $14.48M | (m) | 6.79× |
| 2022-06-30 | $675.18M | $127.53M | $138.78M | (m) | $133.30M | (m) | $37.11M | (m) | 5.29× |
| 2022-03-31 | $765.33M | $141.71M | $353.07M | (m) | $160.26M | (m) | $23.70M | (m) | 5.40× |
| 2021-12-31 | $611.96M | $105.31M | $164.89M | (m) | $138.91M | (m) | $20.49M | (m) | 5.81× |
| 2021-09-30 | $622.84M | $147.16M | $214.88M | (m) | $120.82M | (m) | $24.87M | (m) | 4.23× |
| 2021-06-30 | $566.69M | $121.52M | $100.46M | (m) | $148.58M | (m) | $14.74M | (m) | 4.66× |
| 2021-03-31 | $659.14M | $196.53M | $151.46M | (m) | $216.51M | (m) | $17.44M | (m) | 3.35× |
| 2020-12-31 | $523.62M | $130.12M | $87.43M | (m) | $183.86M | (m) | $26.49M | (m) | 4.02× |
| 2020-09-30 | $195.62M | $57.74M | $53.03M | $21.90M | $90.68M | (m) | $18.67M | (m) | 3.39× |
| 2020-06-30 | $41.18M | $6.51M | $2.43M | $18.53M | $13.86M | (m) | $3.64M | (m) | 6.33× |
| 2020-03-31 | $37.02M | $5.81M | $9.30M | $18.03M | $6.37M | (m) | $2.85M | (m) | 6.37× |
| 2019-12-31 | $37.08M | $3.72M | $11.96M | $16.30M | $6.55M | (m) | $1.58M | (m) | 9.96× |
| 2019-09-30 | $39.20M | $4.25M | $20.52M | $11.60M | $5.29M | (m) | $2.15M | (m) | 9.22× |
| 2019-06-30 | $34.80M | $2.91M | $9.16M | $17.82M | $5.54M | (m) | $1.18M | (m) | 11.96× |
| 2019-03-31 | $36.30M | $3.20M | $5.29M | $24.14M | $4.56M | (m) | $1.46M | (m) | 11.33× |
| 2018-12-31 | $39.54M | $2.74M | $6.74M | $24.30M | $5.95M | (m) | $1.31M | (m) | 14.44× |
| 2018-09-30 | $41.05M | $2.25M | $8.49M | $24.11M | $6.08M | (m) | $1.02M | (m) | 18.20× |
| 2018-06-30 | $38.20M | $2.98M | $3.65M | $26.95M | $5.05M | (m) | $1.79M | (m) | 12.83× |
| 2018-03-31 | $36.08M | $2.41M | $5.27M | $23.21M | $4.97M | (m) | $1.35M | (m) | 14.98× |
| 2017-12-31 | $32.93M | $3.00M | $6.49M | $19.99M | $4.00M | (m) | $2.09M | (m) | 10.98× |
| 2017-09-30 | $32.04M | $3.15M | $9.48M | $16.57M | $3.59M | (m) | $2.37M | (m) | 10.17× |
| 2017-06-30 | $34.73M | $2.83M | $11.47M | $17.40M | $4.19M | (m) | $1.82M | (m) | 12.28× |
| 2017-03-31 | $33.17M | $3.28M | $6.73M | $20.63M | $4.60M | (m) | $2.31M | (m) | 10.11× |
| 2016-12-31 | $26.14M | $3.32M | $7.90M | $12.97M | $4.36M | (m) | $2.76M | (m) | 7.88× |
| 2016-09-30 | $17.49M | $5.01M | (m) | (m) | $4.41M | (m) | $3.29M | (m) | 3.49× |
| 2015-12-31 | $2.93M | $686.00K | $489.00K | (m) | $2.12M | (m) | $314.00K | (m) | 4.27× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |